Literature DB >> 12715127

[How effective are PDE-5 inhibitors?].

K-P Jünemann1.   

Abstract

Efficacy is a deciding factor in the selection of a therapy, also by erectile dysfunction. With PDE-5 inhibitors, efficacy can only be determined using subjective information from the patient. Various methods have been developed to quantify this information. If one attempts to compare Sildenafil, Tadalafil and Vardenafil using currently available data, it is necessary to bear in mind that groups of patients with differing severity of erectile dysfunction and various placebo response rates were examined. In addition, patients for whom Sildenafil did not work were excluded from important studies with Tadalafil and Vardenafil. Taking into consideration these factors, the new drugs show no advantages over Sildenafil. Moreover, detailed data for the counselling of certain patient groups is at present only available for Sildenafil, and there is, in addition, a high degree of patient satisfaction with this drug. The "gold standard" for the therapy of erectile dysfunction is Sildenafil and the effectiveness of all new drugs must be compared to it.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715127     DOI: 10.1007/s00120-003-0331-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  11 in total

1.  Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies.

Authors:  F Montorsi; T E McDermott; R Morgan; A Olsson; A Schultz; H J Kirkeby; I H Osterloh
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

2.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

3.  Health outcomes variables important to patients in the treatment of erectile dysfunction.

Authors:  C Hanson-Divers; S E Jackson; T F Lue; S Y Crawford; R C Rosen
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

4.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

Authors:  R C Rosen; A Riley; G Wagner; I H Osterloh; J Kirkpatrick; A Mishra
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

5.  On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction.

Authors:  H Padma-Nathan; J G McMurray; W E Pullman; J S Whitaker; J B Saoud; K M Ferguson; R C Rosen
Journal:  Int J Impot Res       Date:  2001-02       Impact factor: 2.896

6.  Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus.

Authors:  A J Boulton; J L Selam; M Sweeney; D Ziegler
Journal:  Diabetologia       Date:  2001-10       Impact factor: 10.122

7.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial.

Authors:  H Porst; R Rosen; H Padma-Nathan; I Goldstein; F Giuliano; E Ulbrich; T Bandel
Journal:  Int J Impot Res       Date:  2001-08       Impact factor: 2.896

Review 8.  Sildenafil for male erectile dysfunction: a systematic review and meta-analysis.

Authors:  Howard A Fink; Roderick Mac Donald; Indulis R Rutks; David B Nelson; Timothy J Wilt
Journal:  Arch Intern Med       Date:  2002-06-24

9.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

Authors:  M S Rendell; J Rajfer; P A Wicker; M D Smith
Journal:  JAMA       Date:  1999-02-03       Impact factor: 56.272

10.  Is sildenafil citrate an alternative agent in the evaluation of penile vascular system with color Doppler ultrasound?

Authors:  Tibet Erdoğru; Mustafa F Usta; Kağan Ceken; Türker Köksal; Mutlu Ates; Adnan Kabaalioğlu; Mehmet Baykara
Journal:  Urol Int       Date:  2002       Impact factor: 2.089

View more
  5 in total

1.  [Drug therapy of erectile dysfunction--the current status].

Authors:  D Schultheiss; C G Stief
Journal:  Urologe A       Date:  2003-10       Impact factor: 0.639

Review 2.  [Therapy for organic erectile dysfunction].

Authors:  A J Becker; M Mayer; C G Stief
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

3.  [Erectile function after nerve-sparing radical prostatectomy. Nocturnal early erection as a parameter of postoperative organic erectile integrity].

Authors:  A Bannowsky; H Schulze; C van der Horst; J H Stübinger; F J Martinez Portillo; K P Jünemann
Journal:  Urologe A       Date:  2005-05       Impact factor: 0.639

Review 4.  [Pathophysiology and rehabilitation of erectile dysfunction after nerve-sparing radical prostatectomy].

Authors:  C van der Horst; F J Martinez-Portillo; K P Jünemann
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

Review 5.  Male sexual dysfunction: diagnosis and treatment from a sexological and interdisciplinary perspective.

Authors:  Dirk Rösing; Klaus-Jürgen Klebingat; Hermann J Berberich; Hartmut A G Bosinski; Kurt Loewit; Klaus M Beier
Journal:  Dtsch Arztebl Int       Date:  2009-12-11       Impact factor: 5.594

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.